Stocks of the Hour: Iceni Gold, Avita Medical, Antisense Therapeutics
Stocks of the Hour: Iceni Gold, Avita Medical, Antisense Therapeutics
Iceni Gold (ASX:ICL) has hit a high-grade vein at the Everleigh well in Western Australia. Technical Director David Nixon comments: "The high-grade rock chip results from the vein are supported by the underlying UFF+ soil anomaly, prospectivity indicators and the multiple coincident targets." Shares are trading 53.13 per cent higher at 9.8 cents.
Iceni Gold（澳大利亚证券交易所股票代码：ICL）在西澳大利亚州的Everleigh油井遇到了高等级矿脉。技术总监戴维·尼克松评论说：“来自矿脉的高品质岩屑结果得到了潜在的UFF+土壤异常、前景指标和多个重合目标的支持。”股价上涨53.13％，至9.8美分。
Avita Medical (ASX:AVH) has announced FDA Approval of its spray-on skin cell product RECELL for the treatment of full thickness skin defects. CEO Jim Corbett comments, "The FDA approval now offers surgeons a best-in-class treatment option for a multitude of severe wounds within inpatient and outpatient settings." Shares are trading 14.22 per cent higher at $4.90.
Avita Medical（ASX: AVH）宣布美国食品药品管理局批准其用于治疗全层皮肤缺陷的喷雾式皮肤细胞产品RECELL。首席执行官吉姆·科贝特评论说：“美国食品药品管理局的批准现在为外科医生提供了治疗住院和门诊环境中多种严重伤口的最佳治疗选择。”股价上涨14.22％，至4.90美元。
Antisense Therapeutics (ASX:ANP, US OTC:ATHJY, FSE:AWY) has announced that the first patient has been dosed in the company's Phase IIb Duchenne Muscular Dystrophy Trial. Three patients are currently in the screening phase of the trial. Shares are trading 6.35 per cent higher at 6.7 cents.
Antisense Therapeutics（澳大利亚证券交易所代码：ANP，美国场外交易代码：ATHJY，FSE: AWY）宣布，该公司的IIb期杜兴氏肌肉萎缩症试验已对首位患者进行了给药。目前有三名患者处于试验的筛查阶段。股价上涨6.35％，至6.7美分。
